• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表面活性剂系统的蛋白质。

The proteins of the surfactant system.

作者信息

Johansson J, Curstedt T, Robertson B

机构信息

Dept of Chemistry 1, Karolinska Institutet, Stockholm, Sweden.

出版信息

Eur Respir J. 1994 Feb;7(2):372-91. doi: 10.1183/09031936.94.07020372.

DOI:10.1183/09031936.94.07020372
PMID:8162991
Abstract

The structural and functional integrity of pulmonary surfactant depends on several specific proteins. Two of these, SP-A and SP-D, are large and water-soluble, while SP-B and SP-C are small and very hydrophobic. SP-A is an 18-mer of 26 kDa polypeptide chains and contains N-linked oligosaccharides. Structurally, it can be characterized as a collagen/lectin hybrid. Together with SP-B, SP-A is required for conversion of secreted endogenous surfactant to tubular myelin in the alveolar lining. It also regulates surfactant secretion and reuptake of surfactant lipids by type II cells; these functions are probably receptor mediated. SP-D, a 12-mer of 39 kDa polypeptide chains, is a collagenous glycoprotein with structural similarities to C-type lectins. Both SP-A and SP-D stimulate alveolar macrophages. SP-B is a 79-residue polypeptide that contains three intrachain disulphide bridges. It exists mainly as a homodimer, which is strongly positively charged and may selectively remove anionic and unsaturated lipid species from the alveolar surface film, thereby increasing surface pressure. SP-C is a mainly alpha-helical, extraordinarily hydrophobic polypeptide containing 35 amino acid residues and covalently linked palmitoyl groups. Its alpha-helical portion is inserted into surfactant lipid bilayers. SP-C accelerates the adsorption of lipid bilayers to an interfacial monolayer. In babies with respiratory distress syndrome, the clinical response to treatment with surfactant containing SP-B and SP-C is much faster than in babies treated with protein-free synthetic surfactant. We speculate that, in the near future, surfactant preparations based on recombinant hydrophobic proteins will be available for clinical use.

摘要

肺表面活性物质的结构和功能完整性取决于几种特定的蛋白质。其中两种,即SP - A和SP - D,分子大且水溶性强,而SP - B和SP - C则分子小且疏水性极强。SP - A是由26 kDa多肽链组成的18聚体,含有N - 连接寡糖。在结构上,它可被表征为胶原蛋白/凝集素杂种。与SP - B一起,SP - A是肺泡内衬中分泌的内源性表面活性物质转化为管状髓鞘所必需的。它还调节表面活性物质的分泌以及II型细胞对表面活性物质脂质的再摄取;这些功能可能是由受体介导的。SP - D是由39 kDa多肽链组成的12聚体,是一种与C型凝集素结构相似的胶原糖蛋白。SP - A和SP - D都能刺激肺泡巨噬细胞。SP - B是一种含有三个链内二硫键的79个残基的多肽。它主要以同二聚体形式存在,带强正电荷,可能选择性地从肺泡表面膜中去除阴离子和不饱和脂质种类,从而增加表面压力。SP - C主要是α - 螺旋结构,是一种含有35个氨基酸残基且共价连接棕榈酰基团的极度疏水的多肽。其α - 螺旋部分插入表面活性物质脂质双层中。SP - C加速脂质双层向界面单层的吸附。在患有呼吸窘迫综合征的婴儿中,使用含SP - B和SP - C的表面活性物质治疗的临床反应比使用无蛋白合成表面活性物质治疗的婴儿要快得多。我们推测,在不久的将来,基于重组疏水蛋白的表面活性物质制剂将可用于临床。

相似文献

1
The proteins of the surfactant system.表面活性剂系统的蛋白质。
Eur Respir J. 1994 Feb;7(2):372-91. doi: 10.1183/09031936.94.07020372.
2
Molecular structures and interactions of pulmonary surfactant components.肺表面活性物质成分的分子结构与相互作用。
Eur J Biochem. 1997 Mar 15;244(3):675-93. doi: 10.1111/j.1432-1033.1997.00675.x.
3
Adsorption of pulmonary surfactant protein SP-A to monolayers of phospholipids containing hydrophobic surfactant protein SP-B or SP-C: potential differential role for tertiary interaction of lipids, hydrophobic proteins, and SP-A.肺表面活性物质蛋白SP-A对含有疏水表面活性物质蛋白SP-B或SP-C的磷脂单层的吸附:脂质、疏水蛋白和SP-A三级相互作用的潜在差异作用。
Biochemistry. 2000 May 23;39(20):6083-93. doi: 10.1021/bi992074x.
4
Potential role of surfactant proteins A and D in innate lung defense against pathogens.表面活性蛋白A和D在肺部先天性抵御病原体中的潜在作用
Biol Neonate. 1995;67 Suppl 1:2-17. doi: 10.1159/000244202.
5
Surfactant proteins A and D specifically stimulate directed actin-based responses in alveolar macrophages.表面活性蛋白A和D可特异性刺激肺泡巨噬细胞中基于肌动蛋白的定向反应。
Am J Physiol. 1999 Jan;276(1):L164-74. doi: 10.1152/ajplung.1999.276.1.L164.
6
KGF increases SP-A and SP-D mRNA levels and secretion in cultured rat alveolar type II cells.角质形成细胞生长因子可提高培养的大鼠II型肺泡细胞中表面活性蛋白-A和表面活性蛋白-D的mRNA水平及分泌量。
Am J Respir Cell Mol Biol. 1998 Feb;18(2):168-78. doi: 10.1165/ajrcmb.18.2.2824.
7
Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large-aggregate integrity.不同表面活性剂制剂的表面积循环:表面活性蛋白-A和表面活性蛋白-B对大聚集体的完整性至关重要。
Biochem J. 1994 Jun 1;300 ( Pt 2)(Pt 2):519-24. doi: 10.1042/bj3000519.
8
Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages.表面活性蛋白A而非表面活性蛋白D是大鼠肺泡巨噬细胞吞噬甲型流感病毒的调理素。
Eur J Immunol. 1997 Apr;27(4):886-90. doi: 10.1002/eji.1830270413.
9
The genomics of soluble proteins with collagenous domains: C1q, MBL, SP-A, SP-D, conglutinin, and CL-43.具有胶原结构域的可溶性蛋白质的基因组学:C1q、甘露聚糖结合凝集素、表面活性蛋白A、表面活性蛋白D、凝集素和CL-43。
Behring Inst Mitt. 1993 Dec(93):81-6.
10
Molecular and cellular processing of lung surfactant.肺表面活性物质的分子和细胞加工过程。
FASEB J. 1994 Sep;8(12):957-67. doi: 10.1096/fasebj.8.12.8088461.

引用本文的文献

1
Metabolic dysregulation in pulmonary fibrosis: insights into amino acid contributions and therapeutic potential.肺纤维化中的代谢失调:对氨基酸作用及治疗潜力的见解
Cell Death Discov. 2025 Aug 27;11(1):411. doi: 10.1038/s41420-025-02715-2.
2
Detection of Cytokines and Collectins in Bronchoalveolar Fluid Samples of Patients Infected with and .在感染[具体病原体1]和[具体病原体2]的患者支气管肺泡灌洗样本中细胞因子和凝集素的检测
J Fungi (Basel). 2021 Nov 4;7(11):938. doi: 10.3390/jof7110938.
3
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
血清表面活性剂蛋白 D 在 COVID-19 中升高,并与疾病严重程度相关。
BMC Infect Dis. 2021 Aug 3;21(1):737. doi: 10.1186/s12879-021-06447-3.
4
Repeated Administration of Clinically Relevant Doses of the Prescription Opioids Tramadol and Tapentadol Causes Lung, Cardiac, and Brain Toxicity in Wistar Rats.对Wistar大鼠重复给予临床相关剂量的处方阿片类药物曲马多和氨酚羟考酮会导致肺、心脏和脑毒性。
Pharmaceuticals (Basel). 2021 Jan 27;14(2):97. doi: 10.3390/ph14020097.
5
FGF10 and Human Lung Disease Across the Life Spectrum.FGF10与全生命周期的人类肺部疾病
Front Genet. 2018 Oct 31;9:517. doi: 10.3389/fgene.2018.00517. eCollection 2018.
6
Sustained distribution of aerosolized PEGylated liposomes in epithelial lining fluids on alveolar surfaces.气溶胶化聚乙二醇脂质体在肺泡表面上皮衬液中的持续分布。
Drug Deliv Transl Res. 2016 Oct;6(5):565-71. doi: 10.1007/s13346-016-0310-2.
7
Surfactant proteins, SP-A and SP-D, in respiratory fungal infections: their role in the inflammatory response.表面活性蛋白SP-A和SP-D在呼吸道真菌感染中的作用:它们在炎症反应中的角色
Respir Res. 2016 Jun 1;17(1):66. doi: 10.1186/s12931-016-0385-9.
8
Hydrophobic surfactant proteins strongly induce negative curvature.疏水表面活性蛋白强烈诱导负曲率。
Biophys J. 2015 Jul 7;109(1):95-105. doi: 10.1016/j.bpj.2015.05.030.
9
Static and Dynamic Microscopy of the Chemical Stability and Aggregation State of Silver Nanowires in Components of Murine Pulmonary Surfactant.小鼠肺表面活性剂成分中银纳米线化学稳定性和聚集状态的静态与动态显微镜观察
Environ Sci Technol. 2015 Jul 7;49(13):8048-56. doi: 10.1021/acs.est.5b01214. Epub 2015 Jun 25.
10
Inhalation of silver nanomaterials--seeing the risks.吸入银纳米材料——正视风险。
Int J Mol Sci. 2014 Dec 22;15(12):23936-74. doi: 10.3390/ijms151223936.